COVID-19 Vaccination Status among Pregnant and Postpartum Women-A Cross-Sectional Study on More Than 1000 Individuals.
COVID-19
Tdap vaccine
fetus
maternal–fetal medicine
pregnancy
vaccination
vaccination status
vaccine
vaccine hesitancy
vaccine uptake
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
25 Jul 2022
25 Jul 2022
Historique:
received:
01
07
2022
revised:
19
07
2022
accepted:
21
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Pregnancy is a well-known factor for vaccine hesitancy and immunization remains the most effective form of prevention against coronavirus disease (COVID-19) related complications. The objective was to estimate vaccine uptake and hesitancy rate, characteristics, and factors contributing to a decision-making process among pregnant and postpartum individuals. This was a prospective cross-sectional study on 1033 pregnant (54.1%) and postpartum (45.9%) women conducted between December 2021 and March 2022 in a tertiary center for maternal−fetal medicine. Logistic regression was used to assess characteristics related to the vaccination decision process. Among responders, 74% were vaccinated and 26% were hesitant (9% planning to vaccinate and 17% totally opposed). Only 59.8% were offered a vaccine by healthcare professionals. Women with higher levels of education (OR 2.26, p < 0.0001), who received positive feedback about vaccination (OR 2.74, p = 0.0172), or were informed about COVID-19 complications in pregnancy (OR 2.6, p < 0.0001) were most likely to accept the vaccination. Hesitancy was associated with multiparity (≥3, OR 4.76, p = 0.006), worse educational status (OR 2.29, p < 0.0001), and lack of previous COVID-19 infection (OR 1.89, p < 0.0001). The most common reason for rejection was insufficient safety data (57%). Understanding factors behind vaccination status is crucial in lowering complications in mothers and newborns and targeted action may facilitate the uptake.
Identifiants
pubmed: 35893827
pii: vaccines10081179
doi: 10.3390/vaccines10081179
pmc: PMC9330718
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Epidemiol. 2022 Apr 5;32(4):188-194
pubmed: 35095091
Nat Med. 2022 Mar;28(3):504-512
pubmed: 35027756
Hum Vaccin Immunother. 2022 Nov 30;18(5):2064686
pubmed: 35476032
Ultrasound Obstet Gynecol. 2021 Apr;57(4):573-581
pubmed: 33620113
Am J Obstet Gynecol. 2021 Sep;225(3):303.e1-303.e17
pubmed: 33775692
Womens Health Rep (New Rochelle). 2022 Jun 29;3(1):608-616
pubmed: 35814609
Lancet. 2022 Mar 5;399(10328):907-908
pubmed: 35189078
Am J Obstet Gynecol. 2022 Apr;226(4):459-474
pubmed: 34774821
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Obstet Gynecol. 2020 Aug;136(2):262-272
pubmed: 32544146
BMC Pregnancy Childbirth. 2022 Jan 14;22(1):33
pubmed: 35030996
Int J Environ Res Public Health. 2021 Jul 06;18(14):
pubmed: 34299673
Am J Obstet Gynecol. 2022 Feb;226(2):236.e1-236.e14
pubmed: 34389291
Vaccines (Basel). 2020 Aug 25;8(3):
pubmed: 32854278
J Genet Couns. 2022 Jun 28;:
pubmed: 35763777
Int J Qual Health Care. 2003 Jun;15(3):261-6
pubmed: 12803354
BJOG. 2022 Jul;129(8):1342-1351
pubmed: 35104382
PLoS One. 2020 Jul 9;15(7):e0234827
pubmed: 32645112
N Engl J Med. 2021 Jun 17;384(24):2342-2343
pubmed: 34133864
Vaccines (Basel). 2021 Nov 17;9(11):
pubmed: 34835274
Congenit Anom (Kyoto). 2022 Mar;62(2):54-67
pubmed: 34961973
Am J Obstet Gynecol MFM. 2021 Sep;3(5):100403
pubmed: 34048965
Vaccine. 2014 Apr 17;32(19):2150-9
pubmed: 24598724